This review discusses the standard of care and emerging therapeutic approaches for non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and Merkel cell carcinoma (MCC). NMSCs are the most common skin cancers globally, primarily caused by UV exposure, with other factors such as immune suppression and genetic mutations also contributing. Surgical excision remains the primary treatment, but advanced or metastatic cases require alternative strategies. Recent research has identified new therapeutic targets, leading to the development of Hedgehog pathway inhibitors for BCC and PD-1/PD-L1 inhibitors for cSCC and MCC. Despite their efficacy, these drugs face challenges such as resistance and side effects. Ongoing studies aim to find safer and more effective treatments. For cSCC, surgical excision is the main treatment, with micrographically controlled surgery (MCS) used for high-risk cases. Radiation therapy and topical treatments like imiquimod and 5-fluorouracil are alternatives. Targeted therapies, including EGFR inhibitors, and immunotherapy with PD-1/PD-L1 inhibitors have shown promise. Cemiplimab and pembrolizumab are effective for advanced cSCC. New treatment modalities include PD-1 inhibitors like nivolumab and cosibelimab, as well as oncolytic viruses like T-VEC. For BCC, surgery is the primary treatment, with MCS for high-risk cases. Topical treatments and Hedgehog inhibitors like vismodegib and sonidegib are used. Systemic immunotherapy with PD-1 inhibitors is effective for advanced BCC. New treatments include patidegib and second-generation Hedgehog inhibitors. For MCC, surgical excision is the primary treatment, with adjuvant radiation. Immunotherapy with PD-1/PD-L1 inhibitors like avelumab and pembrolizumab is effective. Targeted therapies and other modalities are under investigation. The review highlights the importance of understanding the pathogenesis of NMSCs and the role of immune suppression, genetic mutations, and environmental factors. Future directions include improving primary and secondary prevention strategies, exploring the tumor microenvironment, and developing more effective and safer treatments. The management of NMSCs will increasingly rely on a holistic approach that addresses both cancer cells and the broader tumor environment.This review discusses the standard of care and emerging therapeutic approaches for non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and Merkel cell carcinoma (MCC). NMSCs are the most common skin cancers globally, primarily caused by UV exposure, with other factors such as immune suppression and genetic mutations also contributing. Surgical excision remains the primary treatment, but advanced or metastatic cases require alternative strategies. Recent research has identified new therapeutic targets, leading to the development of Hedgehog pathway inhibitors for BCC and PD-1/PD-L1 inhibitors for cSCC and MCC. Despite their efficacy, these drugs face challenges such as resistance and side effects. Ongoing studies aim to find safer and more effective treatments. For cSCC, surgical excision is the main treatment, with micrographically controlled surgery (MCS) used for high-risk cases. Radiation therapy and topical treatments like imiquimod and 5-fluorouracil are alternatives. Targeted therapies, including EGFR inhibitors, and immunotherapy with PD-1/PD-L1 inhibitors have shown promise. Cemiplimab and pembrolizumab are effective for advanced cSCC. New treatment modalities include PD-1 inhibitors like nivolumab and cosibelimab, as well as oncolytic viruses like T-VEC. For BCC, surgery is the primary treatment, with MCS for high-risk cases. Topical treatments and Hedgehog inhibitors like vismodegib and sonidegib are used. Systemic immunotherapy with PD-1 inhibitors is effective for advanced BCC. New treatments include patidegib and second-generation Hedgehog inhibitors. For MCC, surgical excision is the primary treatment, with adjuvant radiation. Immunotherapy with PD-1/PD-L1 inhibitors like avelumab and pembrolizumab is effective. Targeted therapies and other modalities are under investigation. The review highlights the importance of understanding the pathogenesis of NMSCs and the role of immune suppression, genetic mutations, and environmental factors. Future directions include improving primary and secondary prevention strategies, exploring the tumor microenvironment, and developing more effective and safer treatments. The management of NMSCs will increasingly rely on a holistic approach that addresses both cancer cells and the broader tumor environment.